Scientific Publication Macrocyclisation process

[Poster Request]

Nanocyclix: next generation kinase therapeutics | A chemocentric approach for the discovery of selective kinase inhibitors

Christopher HOUSSEMAN, Pascal BENDERITTER, Petra BLOM, Marie-Hélène FOUCHET, Alexis DENIS and Jan HOFLACK

Hearquarters: 20, rue Jean Mazen | B.P. 27627 | FR-21076 Dijon Cedex | France
Research Center: 25-27 | avenue du Québec | FR-91140 Villebon-sur-Yvette | France

Our kinase focused library of small macrocycles so called Nanocyclix is designed in a chemocentric approach to identify attractive and selective kinase inhibitors across the kinome. All compounds are in the drug-like properties space and hit compounds display nM potencies and good selectivity against a small number of kinases.

Nanocyclix® Oncodesign's proprietary medicinal chemistry technology is used in its drug discovery programs. Conceptually, the Nanocyclix® technology is based on the macrocyclization paradigm of known hinge binder scaffolds resulting in tighter binding site recognition, potency and selectivity towards the ATP site. Exploring different lengths and functionalities of the cyclic linker allows to populate the conformational space of every template and to identify an optimal match between the size and mobility of the binding site and the macrocyclic ligand.

Extensive profiling of the full Nanocyclix collection allows selecting and valorizing the most attractive compounds and scaffold-linker combinations at an early stage. Typically, Nanocyclix are profiled against broad panel of kinases in biochemical assays and eADMET parameters.

Poster Request Form - 2nd RSC ANMC Symposium

Invalid Input

Invalid Input

Invalid Input

your address is not a proper one. Please check.

We care about your privacy.
Since you are a valuable customer or prospect, we want to make sure that you can choose to stay connected with Oncodesign. Oncodesign collectgs your data to provide you with information regarding our offering and news.
In accordance with the law "Informatique et Libertés", you can exercise your right of access to the data concerning you and have them rectified by contacting
Your Email address has not been and will not be given to third parties. 
Oncodesign is registered with CNIL under number 2102182.